Clinical Trial Update: Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating solifenacin for mitigation of ureteral stent–induced pain and lower urinary tract symptoms has completed, with results posted in 2012…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Solifenacin (solifenacin)

Snippet

Sponsor: Barrie Urology Associates | Conditions: Flank Pain, Urinary Bladder, Overactive | Phase 4 | Status: COMPLETED | Results posted: 2012-08-22